Pediatrix Medical Group, Inc.

Valuation Analysis

About the Company

Pediatrix Medical Group, Inc. en bref

Pediatrix Medical Group, Inc. (MD) is currently trading at 20,58 € with a market capitalization of 1,7 Md €. The trailing P/E ratio stands at 11.46x, with a forward P/E of 10.01x. The 52-week range spans from 10,32 € to 21,79 €; the current price is 5.5% below the yearly high. Year-over-year revenue growth stands at +3.9%. The net profit margin stands at 9.02%.

💰 Dividende

Pediatrix Medical Group, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

6 analystes évaluent Pediatrix Medical Group, Inc. (MD) au consensus : None. L'objectif de cours moyen est de 20,20 €, soit un potentiel de -1.88% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 16,56 € à 23,54 €.

Pediatrix Medical Group, Inc. : la thèse d'investissement en détail

Pediatrix Medical Group, Inc. (MD) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 50% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

Revenue growth has slowed to just 3.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

Valorisation en contexte

With a PEG ratio of 0.24, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 8.55x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 10.01x is meaningfully below the trailing 11.46x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (5.81%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Pediatrix Medical Group, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.